Mentice AB (FRA:MN2) Growth Rank: 7 (As of Sep. 04, 2026) — 13% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MN2 Mentice AB FRA:MN2
75 GF Score
Price €1.20
GF Value €1.89
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Mentice AB Growth Rank?

Mentice AB FRA:MN2 +1.27% 75 Growth Rank is 7 as of Sep. 04, 2026, which is 13% below its 10-year median of 8.00. GuruFocus rates FRA:MN2 with a GF Score™ of 75/100 and a GF Value™ of €1.89 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Mentice AB has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

FRA:MN2 vs ABT, SYK, MDT: Growth Rank Comparison

For the Medical Devices subindustry, Mentice AB's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mentice AB Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's Growth Rank distribution charts can be found below:

* The bar in red indicates where Mentice AB's Growth Rank falls into.


FRA:MN2
75GF Score
Mentice AB FRA:MN2
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Mentice AB (FRA:MN2) has a Growth Rank of 7 as of Sep. 04, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Mentice AB and its competitors. This is 13% below median its historical median of 8.00. Over the past decade, Mentice AB's Growth Rank has ranged from 2.00 to 9.00.
Is Mentice AB's Growth Rank too high?
Mentice AB's current Growth Rank of 7 is 13% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. Overall, Mentice AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's Growth Rank compare to ABT and SYK?
Mentice AB's Growth Rank of 7 can be compared against companies in the Medical Devices & Instruments industry. Historically, Mentice AB's own Growth Rank has ranged from 2.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Mentice AB and its competitors. Mentice AB's current Growth Rank is 7, which is 13% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (FRA:MN2) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.89, compared to a current price of €1.20 — trading 36.8% below its estimated fair value. The current Growth Rank is 7, which is 13% below median its 10-year median of 8.00. Mentice AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Mentice AB (FRA:MN2), the current Growth Rank is 7 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mentice AB (FRA:MN2) Overvalued in 2026?

Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued. The current stock price of €1.20 is trading 36.8% below its estimated GF Value™ of €1.89. GuruFocus considers Mentice AB to be Significantly Undervalued.

Key valuation signals for FRA:MN2:

  • Growth Rank: 7 (13% below median its 10-year median of 8.00)
  • GF Value™: €1.89 vs. price of €1.20 (36.8% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the FRA:MN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mentice AB Business Description

Other Exchanges MNTC:Sweden
Address Odinsgatan 10, Gothenburg, SWE, 411 03
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
75GF Score

Get the complete analysis for FRA:MN2

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.20
Price
€1.89
GF Value